Summary - Funding Rounds

Founding Date

1998
Keryx Biopharmaceuticals is a subsidiary of Akebia Therapeutics

Keryx Biopharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7.0m10.8m13.7m32.0m60.6m

Revenue growth, %

55%26%134%

Cost of goods sold

4.5m37.8m22.0m

Gross profit

9.2m(5.8m)38.7m

Gross profit Margin, %

67%(18%)64%

R&D expense

36.7m29.5m37.7m

General and administrative expense

81.4m84.6m99.6m

Operating expense total

54.1m124.7m154.7m162.3m

EBIT

(47.1m)(111.2m)(111.1m)(122.8m)(101.7m)

EBIT margin, %

(673%)(1028%)(812%)(384%)(168%)

Interest income

351.0k411.0k

Pre tax profit

(46.7m)(110.8m)(123.1m)(161.0m)(163.7m)

Income tax expense

700.0k90.0k80.0k(235.0k)

Net Income

(46.7m)(111.5m)(123.1m)(161.1m)(163.4m)

Keryx Biopharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

55.7m74.3m200.3m111.8m93.5m

Accounts Receivable

834.0k3.7m5.2m8.1m

Inventories

7.8m41.9m12.7m28.7m

Current Assets

56.9m98.6m249.3m132.9m141.6m

PP&E

349.0k1.5m5.1m4.2m4.5m

Goodwill

3.2m3.2m3.2m3.2m3.2m

Total Assets

60.8m103.6m258.7m141.4m158.9m

Accounts Payable

14.0m24.1m21.3m21.2m45.0m

Current Liabilities

15.3m29.3m77.6m21.6m45.4m

Total Liabilities

15.4m171.8m149.7m173.0m

Additional Paid-in Capital

485.0m624.6m761.2m827.1m984.7m

Retained Earnings

(439.3m)(550.9m)(674.0m)(835.1m)(998.5m)

Total Equity

45.4m73.5m86.9m(8.3m)(14.1m)

Financial Leverage

1.3 x1.4 x3 x-17 x-11.3 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

67.7m105.3m92.0m84.1m168.8m131.3m102.2m170.5m155.8m132.2m90.9m140.5m114.0m60.1m49.5m41.1m

Accounts Receivable

156.0k195.0k136.0k151.0k1.3m1.4m2.6m4.3m5.1m6.2m8.5m9.2m12.9m15.4m14.6m

Inventories

918.0k27.2m34.0m36.7m42.2m39.7m24.3m12.6m18.1m26.0m35.4m48.6m58.7m

Current Assets

71.6m156.4m138.3m122.0m200.7m171.4m147.7m220.2m202.7m160.0m119.3m175.7m164.8m119.5m125.6m126.4m

PP&E

71.0k538.0k1.0m1.4m1.5m1.4m2.6m5.0m4.8m4.4m4.0m4.2m4.7m4.3m4.1m3.8m

Goodwill

3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m3.2m

Total Assets

75.1m160.3m142.9m126.9m205.7m177.2m154.7m229.5m211.7m168.6m127.7m184.2m173.8m140.1m145.7m151.8m

Accounts Payable

15.9m16.0m17.2m25.1m33.1m21.5m23.9m13.7m14.7m13.1m21.8m30.1m36.5m44.5m54.6m56.7m

Current Liabilities

16.5m16.4m18.5m28.1m36.4m27.3m30.6m70.1m23.4m18.3m22.1m30.5m36.9m44.9m55.0m57.1m

Total Liabilities

16.5m16.4m18.6m28.2m37.2m30.0m33.6m180.1m151.9m146.6m150.2m158.5m164.9m171.7m186.8m206.0m

Additional Paid-in Capital

480.5m597.1m599.9m609.5m747.4m752.9m757.5m764.6m819.7m823.6m835.8m970.5m977.3m988.4m1.0b1.0b

Retained Earnings

(421.7m)(452.9m)(475.3m)(510.6m)(578.6m)(605.5m)(636.2m)(715.0m)(759.6m)(801.3m)(858.1m)(944.6m)(968.1m)(1.0b)(1.0b)(1.1b)

Total Equity

58.6m143.9m124.3m98.7m168.5m147.1m121.1m49.4m59.9m22.0m(22.5m)25.6m9.0m(31.6m)(41.2m)(54.2m)

Financial Leverage

1.3 x1.1 x1.1 x1.3 x1.2 x1.2 x1.3 x4.6 x3.5 x7.7 x-5.7 x7.2 x19.4 x-4.4 x-3.5 x-2.8 x

Keryx Biopharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(46.7m)(111.5m)(123.1m)(161.1m)(163.4m)

Depreciation and Amortization

54.0k306.0k596.0k1.0m937.0k

Accounts Receivable

(834.0k)(2.8m)(1.6m)(2.9m)

Inventories

(7.8m)(29.2m)(2.3m)(19.5m)

Accounts Payable

6.8m10.1m(9.2m)88.0k24.0m

Cash From Operating Activities

(34.3m)(81.0m)(127.5m)(86.6m)(93.5m)

Purchases of PP&E

(346.0k)(1.5m)(2.8m)(2.1m)(1.3m)

Cash From Investing Activities

(346.0k)(13.0m)8.7m(2.1m)(1.3m)

Cash From Financing Activities

75.7m112.6m244.7m198.0k76.5m
Report incorrect company information

Keryx Biopharmaceuticals Employee Rating

4.110 votes
Culture & Values
3.6
Work/Life Balance
4.0
Senior Management
3.5
Salary & Benefits
4.3
Career Opportunities
3.3
Source